FDA Approved: FRAGMIN — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA page indicates Pfizer's supplemental application for FRAGMIN (dalteparin sodium) under NDA 020287 is under consideration for a supplemental change to its ap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism

Drugs mentioned

• FRAGMIN (DALTEPARIN SODIUM)

Snippet

SUPPL AP for FRAGMIN (DALTEPARIN SODIUM)